Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/16/24 17:08 | 5/15/24 | DNA | Health | BioPrd | Biological Products, (No Diag | Sankar Shyam | MA | D | 1 | P | 515 | 0.8236 | 0 | 625 | 36 | 2,357 | D | |||||||||||||||
5/14/24 17:16 | 5/14/24 | DNA | Health | BioPrd | Biological Products, (No Diag | Sloan Harry | MA | D | 1 | P | 272 | 0.9133 | 0 | 298 | 71 | 719 | D | |||||||||||||||
5/14/24 17:13 | 5/14/24 | DNA | Health | BioPrd | Biological Products, (No Diag | Dekkers Marijn E | MA | D | 1 | S | -1,606 | 0.9300 | 0 | -1,727 | 6,062 | D | ||||||||||||||||
5/6/24 16:55 | 5/1/24 | DNA | Health | BioPrd | Biological Products, (No Diag | Dmytruk Mark E. | MA | O | See Rema | 6 | M.d | 143 | 0.3253 | 0 | 439 | 90 | 925 | D | ||||||||||||||
5/6/24 16:55 | 5/2/24 | DNA | Health | BioPrd | Biological Products, (No Diag | Dmytruk Mark E. | MA | O | See Rema | 6 | S.d | -143 | 0.3253 | 0 | -439 | 925 | D | |||||||||||||||
5/6/24 16:53 | 5/1/24 | DNA | Health | BioPrd | Biological Products, (No Diag | Coen Steven P. | MA | O | See rema | 2 | M.d | 111 | 0.2615 | 0 | 426 | 163 | D | |||||||||||||||
5/6/24 16:53 | 5/2/24 | DNA | Health | BioPrd | Biological Products, (No Diag | Coen Steven P. | MA | O | See rema | 2 | S.d | -111 | 0.2615 | 0 | -426 | 163 | D |
D | Derivative transaction in filing (usually option exercise) |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
A | Amended filing |
E | Error detected in filing |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |